- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT07890935
Effects of Root Extract Ashwagandha (KSM-66) on Perception of Recovery and Muscle Strength in Adolescents Aged 11 to 19 Engaged in Grassroots Football
Effects of KSM-66 Ashwagandha (Withania Somnifera) Root Extract Supplementation on Perception of Recovery and Muscle Strength in Adolescents in Grassroots Football: A Randomised, Double-Blind, Placebo-Controlled Trial
This study will test whether six weeks of ashwagandha (KSM-66 root extract), helps teenage footballers recover and improve strength. Very little research has looked at young people aged 11 to 19, despite increased usage in this cohort.
About 50 to 60 male and female players from grassroots clubs in Sussex, Surrey and Greater London will be randomly assigned to take a daily capsule of either 450 mg ashwagandha or a placebo in an unblinded fashion. Before and after the six weeks, players will do tests at their usual training site: saliva samples to measure the cortisol, grip strength, a 1 km time trial, and short questionnaires on recovery, sleep, stress and soreness.
The results will show whether ashwagandha changes stress, strength, performance and perceived recovery over six weeks.
A tanulmány áttekintése
Állapot
Körülmények
Beavatkozás / kezelés
Részletes leírás
This randomised, double-blind, placebo-controlled trial will test whether KSM-66 ashwagandha (Withania somnifera) root extract alters physiological stress, neuromuscular performance and perceived recovery in adolescent footballers. In adults, standardised root extract has been associated with improved strength, recovery, sleep and reduced cortisol. In children, the only placebo-controlled trial of root extract (ages 6 to 12) examined cognition and sleep. No trial has studied adolescents, whose growth, maturation and training load may alter responses, so adult findings cannot be assumed to apply.
An independent collaborator outside the research team will generate the allocation (block size four, stratified by sex and age band, 11 to 15 and 16 to 19) and label bottles with participant codes only. Participants, caregivers and investigators will remain blind until the dataset is locked, and blinding success will be assessed at follow-up. Players aged 11 to 15 take part with parental consent and their own assent, and players aged 16 to 19 consent for themselves. A study medical official will screen medical eligibility. Caregivers or participants will be contacted weekly regarding adverse events, and any suspected supplement-related event will lead to discontinuation and medical review within 24 hours.
Data will be analysed by linear mixed methods. Two investigators will analyse the coded data independently and blind to allocation. Results will be interpreted as short-term responses and will not establish long-term safety or efficacy.
Tanulmány típusa
Beiratkozás (Becsült)
Fázis
- Nem alkalmazható
Kapcsolatok és helyek
Tanulmányi kapcsolat
- Név: Alex Levington, PhD(c)
- Telefonszám: 07882461098
- E-mail: alex@strengthandnutrition.co.uk
Tanulmányozza a kapcsolattartók biztonsági mentését
- Név: Olivia C Coope, PhD(c)
- E-mail: occ@spartaresearch.org
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Leírás
Inclusion Criteria:
- Aged 11 to 19 years on the day of baseline testing
- Male or female player registered with a participating grassroots football club or community football programme, taking part in organised football training at least once a week (any playing ability)
- Able to attend both testing sessions and able to swallow a capsule
- Valid written consent: parent/caregiver consent and player assent (ages 11 to 17), or the player's own consent (ages 18 to 19)
Exclusion Criteria:
- Diagnosed liver, kidney or thyroid condition
- Autoimmune condition (e.g. type 1 diabetes, lupus, rheumatoid or juvenile idiopathic arthritis, inflammatory bowel disease)
- Diabetes or another condition affecting blood sugar; high or low blood pressure requiring treatment
- Regularly taking prescribed medication
- Known allergy or intolerance to ashwagandha, nightshade family plants, corn (maize) or the capsule shell
- Pregnant, possibly pregnant or breastfeeding
- Stomach ulcer; heart condition; chest pain, fainting or seizures during exercise; or medical advice not to do hard exercise
- Current illness or injury that prevents maximal effort
- Surgery planned during the study or within 2 weeks after it, or hospital admission in the last 3 months
- Currently taking, or taken in the past 4 weeks, ashwagandha in any form, including combination products
- Unwilling to avoid starting any new supplement during the six weeks
- Taking part in another research study involving a supplement or medicine in the past 3 months
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Alapvető tudomány
- Kiosztás: Véletlenszerűsített
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Hármas
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
|---|---|
|
Kísérleti: Root extract Ashwagandha
450mg of KSM-66 Ashwagandha |
One 450 mg capsule of KSM-66 ashwagandha, taken once daily with a meal for six weeks (42 days). KSM-66 is a full-spectrum extract made from root only, with no leaf, standardised to 5% withanolides (HPLC verified), and supplied with a certificate of analysis for each batch. Capsules are supplied in labelled bottles of 42 and are identical in appearance to the placebo.
Más nevek:
|
|
Placebo Comparator: Placebo
450mg corn starch |
One 450 mg capsule of corn starch, taken once daily with a meal for six weeks (42 days). The capsule shell, appearance, bottle and labelling are identical to the active capsule. |
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Salivary cortisol
Időkeret: Baseline (week 0) and after six weeks of supplementation
|
Saliva collected with Salivette tubes after an evening training session and analysed by an external laboratory. Reported as the change from baseline to follow-up. |
Baseline (week 0) and after six weeks of supplementation
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Salivary alpha-amylase
Időkeret: Baseline (week 0) and after six weeks of supplementation
|
Measured from the same saliva samples as cortisol. |
Baseline (week 0) and after six weeks of supplementation
|
|
Handgrip Strength
Időkeret: Baseline (week 0) and after six weeks of supplementation
|
Maximal handgrip strength measured with a CAMRY handgrip dynamometer. |
Baseline (week 0) and after six weeks of supplementation
|
|
Number of participants with adverse events
Időkeret: Baseline (week 0) and after six weeks of supplementation
|
Any adverse events reported in the duration of the clinical trial |
Baseline (week 0) and after six weeks of supplementation
|
|
Change in perceived recovery, measured by the Hooper Index
Időkeret: Baseline (week 0) and after six weeks of supplementation
|
Self-reported fatigue, stress, sleep quality and muscle soreness on the Hooper Index questionnaire. Individual items are scored 1 (very, very good) to 10 (very, very bad) and the total score is 4 to 40, higher scores indicating poorer recovery. |
Baseline (week 0) and after six weeks of supplementation
|
|
Change in 1 km time-trial performance
Időkeret: Baseline (week 0) and after six weeks of supplementation
|
Time taken to complete a 1 km run, as a measure of aerobic fitness and high-intensity running capacity. |
Baseline (week 0) and after six weeks of supplementation
|
Együttműködők és nyomozók
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Becsült)
Elsődleges befejezés (Becsült)
A tanulmány befejezése (Becsült)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
Kulcsszavak
További vonatkozó MeSH feltételek
Egyéb vizsgálati azonosító számok
- ASH-ADOL-001
Terv az egyéni résztvevői adatokhoz (IPD)
Tervezi megosztani az egyéni résztvevői adatokat (IPD)?
IPD terv leírása
Individual participant data will not be shared. Participants will be minors recruited from a small number of local football clubs, so a dataset of this size (about 50 to 60 players) combined with age, sex and test results could allow re-identification even after coding. Consent and assent were obtained for use of the data within this study only, and the participant code key and contact details will be permanently deleted on 31 May 2027. The fully anonymised dataset will be held securely by the research team and used only for the analyses and publications described in the ethics-approved protocol. Summary results will be reported in the results section of this record and in peer-reviewed publication, with participating clubs not named.
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .